Nothing Special   »   [go: up one dir, main page]

BR112012028764A2 - anticor-pos antifgfr2 - Google Patents

anticor-pos antifgfr2

Info

Publication number
BR112012028764A2
BR112012028764A2 BR112012028764A BR112012028764A BR112012028764A2 BR 112012028764 A2 BR112012028764 A2 BR 112012028764A2 BR 112012028764 A BR112012028764 A BR 112012028764A BR 112012028764 A BR112012028764 A BR 112012028764A BR 112012028764 A2 BR112012028764 A2 BR 112012028764A2
Authority
BR
Brazil
Prior art keywords
antifgfr2
pos
disorders
antibodies
gffr2
Prior art date
Application number
BR112012028764A
Other languages
English (en)
Inventor
Bai Ailin
Gyuris Jeno
Meetze Kristan
Weiler Solly
Chen Ting
m jr winston William
Weng Zhigang
Original Assignee
Aveo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals Inc filed Critical Aveo Pharmaceuticals Inc
Publication of BR112012028764A2 publication Critical patent/BR112012028764A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

anticor-pos antifgfr2. a presente invenção refere-se aos anticorpos monocionais que se ligam e inibem as atividades biológicas do fgfr2 humano são divulgados. os anticorpos podem ser utilizados para tratar doenças e distúrbios proliferativos das células, incluindo certas formas de câncer, associados à ativação sobre-expressão do fgfr2.
BR112012028764A 2010-05-11 2011-05-11 anticor-pos antifgfr2 BR112012028764A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33359010P 2010-05-11 2010-05-11
PCT/US2011/036085 WO2011143318A2 (en) 2010-05-11 2011-05-11 Anti-fgfr2 antibodies

Publications (1)

Publication Number Publication Date
BR112012028764A2 true BR112012028764A2 (pt) 2017-03-14

Family

ID=44914959

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012028764A BR112012028764A2 (pt) 2010-05-11 2011-05-11 anticor-pos antifgfr2

Country Status (15)

Country Link
US (2) US8481688B2 (pt)
EP (1) EP2569012A4 (pt)
JP (1) JP2013529076A (pt)
KR (1) KR20130065665A (pt)
CN (1) CN102905723A (pt)
AU (1) AU2011253101A1 (pt)
BR (1) BR112012028764A2 (pt)
CA (1) CA2800311A1 (pt)
IL (1) IL222852A0 (pt)
MX (1) MX2012013068A (pt)
NZ (1) NZ603972A (pt)
RU (1) RU2012153241A (pt)
SG (1) SG185487A1 (pt)
WO (1) WO2011143318A2 (pt)
ZA (1) ZA201209004B (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
AU2012300279A1 (en) 2011-08-26 2014-04-03 Merrimack Pharmaceuticals, Inc. Tandem Fc bispecific antibodies
AR088941A1 (es) * 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
JP6188681B2 (ja) 2012-04-09 2017-08-30 第一三共株式会社 抗ｆｇｆｒ２抗体
US9708601B2 (en) * 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
NZ702747A (en) 2012-06-13 2017-03-31 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
WO2014089193A1 (en) * 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CN103145843B (zh) * 2013-02-20 2014-10-29 暨南大学 抗成纤维细胞生长因子受体的单链抗体
WO2014138449A1 (en) 2013-03-06 2014-09-12 Merrimack Pharmaceuticals, Inc. Anti-c-met tandem fc bispecific antibodies
EP2986610B9 (en) 2013-04-19 2018-10-17 Incyte Holdings Corporation Bicyclic heterocycles as fgfr inhibitors
DK3027651T3 (en) * 2013-08-01 2019-04-15 Five Prime Therapeutics Inc AFUCOSYLED ANTI-FGFR2IIIB ANTIBODIES
ES2768618T3 (es) * 2013-10-08 2020-06-23 Daiichi Sankyo Co Ltd Combinación de anticuerpo anti-FGFR2 y otro agente
JP6594875B2 (ja) 2013-12-03 2019-10-23 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 細胞傷害性抗体
US10780182B2 (en) 2014-04-25 2020-09-22 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
PE20170261A1 (es) 2014-05-13 2017-04-12 Univ Pennsylvania Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9708318B2 (en) 2015-02-20 2017-07-18 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
TW201642904A (zh) * 2015-04-08 2016-12-16 第一三共股份有限公司 含抗ｆｇｆｒ２抗體及其他藥劑之組成物
CA3003252C (en) 2015-10-28 2024-06-25 Yale University Humanized anti-dkk2 antibody and uses thereof
TWI791422B (zh) 2015-11-23 2023-02-11 美商戊瑞治療有限公司 用於癌症治療之單獨fgfr2抑制劑或與免疫刺激劑組合
PL238516B1 (pl) 2016-06-13 2021-08-30 Univ Wroclawski Sposób otrzymywania modyfikowanego polipeptydu
CN107513106A (zh) * 2016-06-17 2017-12-26 艾托金生物医药（苏州）有限公司 抗FGFR2-IIIc单克隆抗体、杂交瘤细胞株和应用
US11091555B2 (en) 2017-05-16 2021-08-17 Five Prime Therapeutics, Inc. Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 chemotherapy
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP3765077A4 (en) * 2018-03-14 2022-01-05 Technion Research & Development Foundation Limited PROGNOSTIC BIOMARKER IN CANCER
IL312465A (en) 2018-05-04 2024-06-01 Incyte Corp FGFR inhibitor solid forms and processes for their preparation
CR20200591A (es) 2018-05-04 2021-03-31 Incyte Corp Sales de un inhibidor de fgfr
US20220025040A1 (en) * 2018-12-07 2022-01-27 The Brigham And Women's Hospital, Inc. Humanized and Affinity-Matured Anti-CEACAM1 Antibodies
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TW202128685A (zh) 2019-10-14 2021-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
US20230034817A1 (en) 2021-04-12 2023-02-02 Affinia Therapeutics Inc. Recombinant aav for treatment of neural disease
WO2023113806A1 (en) 2021-12-16 2023-06-22 Affinia Therapeutics, Inc. Recombinant aav for treatment of neural disease
JP2024515788A (ja) 2021-04-27 2024-04-10 ジェネレーション バイオ カンパニー 治療抗体を発現する非ウイルスｄｎａベクター及びその使用
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
AU2023235112A1 (en) 2022-03-14 2024-10-17 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use
CN116284396A (zh) * 2022-12-20 2023-06-23 合肥天港免疫药物有限公司 NKp46抗体及其用途
CN118852431A (zh) * 2023-04-28 2024-10-29 武汉人福创新药物研发中心有限公司 抗FGFR2b单抗

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0481000T3 (da) 1989-07-06 1999-11-15 Univ California Receptorer for fibroblastvækstfaktorer
EP0538404B1 (en) 1990-07-06 2003-06-18 Rhone-Poulenc Rorer International (Holdings) Inc. Fibroblast growth factor receptors
US5863888A (en) 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
US6541212B2 (en) * 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
CA2407352A1 (en) * 2000-04-21 2001-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of acne vulgaris
EP1197755A1 (en) * 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification of protein binding sites
US20040116330A1 (en) 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
WO2003046012A1 (en) * 2001-11-30 2003-06-05 Crucell Holland B.V. Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation
US20080219974A1 (en) * 2002-03-01 2008-09-11 Bernett Matthew J Optimized antibodies that target hm1.24
IL149820A0 (en) * 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US20050282733A1 (en) 2002-06-27 2005-12-22 Prins Johannes B Differentiation modulating agents and uses therefor
NZ537965A (en) * 2002-07-01 2008-04-30 Biogen Idec Inc Humanized anti-lymphotoxin beta receptor antibodies
MXPA05005470A (es) 2002-11-20 2005-09-08 Cancer Rec Tech Ltd Anticuerpos, polipeptidos y usos de los mismos.
KR20070001883A (ko) * 2003-12-08 2007-01-04 이뮤노젠 아이엔씨 항-아이쥐에프-아이 수용체 항체
AU2004312376A1 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
EP1612224B1 (en) 2004-06-29 2012-03-07 B.R.A.H.M.S GmbH Novel monoclonal thyroid stimulating or blocking antibodies, peptide sequences corresponding to their variable regions, and their uses in diagnostic, preventive and therapeutic medicine
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2007240315A1 (en) * 2006-04-20 2007-11-01 Amgen Inc. GLP-1 compound/glucagon antibody compositions
EP2018442A2 (en) 2006-05-12 2009-01-28 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
CA2655504A1 (en) * 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
EP2548576B1 (en) 2006-08-14 2016-11-30 Chugai Seiyaku Kabushiki Kaisha Diagnosis of cancer using anti-desmoglein-3 antibodies
JP2010501161A (ja) * 2006-08-18 2010-01-21 オンコセラピー・サイエンス株式会社 Ｒｅｇ４またはｋｉａａ０１０１を過剰発現している癌の治療または予防
CA2669049A1 (en) 2006-11-09 2008-11-06 Sudhir Paul Binary epitope antibodies and b cell superantigen immune stimulants
MX2009006659A (es) * 2006-12-20 2009-10-12 Mmr Information Systems Inc Anticuerpos y metodos de elaboracion y uso.
WO2008118877A2 (en) * 2007-03-23 2008-10-02 The Translational Genomics Research Institute Method of diagnosing, classifying and treating endometrial cancer and precancer
EP3689912A1 (en) * 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
DK2236604T3 (en) * 2007-12-05 2016-10-03 Chugai Pharmaceutical Co Ltd The anti-NR10 antibody and use thereof
US20110059091A1 (en) 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
TWI445716B (zh) * 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
WO2010040083A2 (en) 2008-10-03 2010-04-08 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Gene expression predictors of chemoresistance
PL2365828T3 (pl) * 2008-11-07 2015-04-30 Galaxy Biotech Llc Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów
US20120301482A1 (en) 2009-08-25 2012-11-29 National Jewish Health Methods and compositions for treatment of lung injury
CN103201287B (zh) 2010-08-12 2016-04-13 艾托生物有限公司 成纤维细胞生长因子受体2的致癌异构体的抗体分子及其用途

Also Published As

Publication number Publication date
WO2011143318A3 (en) 2012-01-05
RU2012153241A (ru) 2014-06-20
MX2012013068A (es) 2013-03-05
AU2011253101A2 (en) 2013-05-02
US8481688B2 (en) 2013-07-09
EP2569012A4 (en) 2013-10-30
US20110305687A1 (en) 2011-12-15
AU2011253101A1 (en) 2013-01-10
KR20130065665A (ko) 2013-06-19
CN102905723A (zh) 2013-01-30
SG185487A1 (en) 2012-12-28
NZ603972A (en) 2014-11-28
EP2569012A2 (en) 2013-03-20
IL222852A0 (en) 2012-12-31
US20130288305A1 (en) 2013-10-31
ZA201209004B (en) 2013-08-28
JP2013529076A (ja) 2013-07-18
WO2011143318A2 (en) 2011-11-17
CA2800311A1 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
BR112012028764A2 (pt) anticor-pos antifgfr2
AR080873A1 (es) Anticuerpos contra factor de crecimiento epidermico (anti-erbb3 o anti-her3)
BR112013010544A2 (pt) moléculas de ligação ao egfr e imunoconjugados das mesmas
PH12015500114A1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
BR112017003505A2 (pt) anticorpos e receptores de antígeno quiméricos específicos para cd19
BR112014007382A2 (pt) anticorpos anti-erbb3 e seus usos
EA201400991A1 (ru) Комбинированная терапия с использованием антител к человеческому csf-1r и ее применения
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
EA201991214A1 (ru) Антитела против pd-1 и их композиции
BR112017003582A2 (pt) anticorpos, composições e usos
CR20110631A (es) Inmunoglobulina con dominio variable dual y usos de la misma
ECSP13012402A (es) Inmunoglobulinas con dominio variable dual y su uso
ECSP12011694A (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2-humana
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
UY35399A (es) Conjugados de fármacos con anticuerpos
CO6771416A2 (es) Inmunoglobulinas de dominio variable dual biespecíficas de il-1 alfa y beta y su uso
ECSP13012462A (es) Inmunoglobulinas con dominio variable dual
BR112013007314A2 (pt) anticorpos anti-cd48 e seus usos
EA201400993A1 (ru) Антитела против рецептора эпидермального фактора роста, активные в определенных условиях, и способы их применения
BR112015023797A2 (pt) proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
UY31862A (es) Inmunoglobulina con dominio variable dual y usos de la misma
NZ595641A (en) Humanized anti-egfl7 antibodies and methods using same
BR112013005145A2 (pt) anticorpos anti-cxcl13 e métodos para seu uso
MX2013010557A (es) Anticuerpo del factor tisular humano y usos de este.
MX2015008313A (es) Terapia de combinacion de anticuerpos anti-her3.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]